Bacteria
The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.
1. A method of preventing or treating a gastrointestinal disorder comprising: administering to a subject in need thereof a pharmaceutically effective amount of bacteria, wherein the bacteria comprise Lactobacillus acidophilus DSM 32111, Lactobacillus brevis DSM 32108, Lactobacillus brevis DSM 32107, Lactobacillus acidophilus DSM 32098, Lactobacillus fermentum DSM 32104, Lactobacillus fermentum DSM 32112, Lactobacillus fermentum DSM 32109, Lactobacillus fermentum DSM 32105, Lactobacillus fermentum DSM 32110, Lactobacillus gasseri DSM 32103 , Lactobacillus mucosae DSM 32099 , Lactobacillus paracasei DSM 32106 , Lactobacillus paracasei DSM 32097 , Lactobacillus rhamnosus DSM 32114 and/or Lactobacillus rhamnosus DSM 32115.
2. A method of claim 1 , wherein the method comprises administering to the subject a pharmaceutically effective amount of Lactobacillus acidophilus DSM 32111, Lactobacillus brevis DSM 32108, Lactobacillus brevis DSM 32107 , Lactobacillus acidophilus DSM 32098, Lactobacillus fermentum DSM 32104, Lactobacillus fermentum DSM 32112, Lactobacillus fermentum DSM 32109, Lactobacillus fermentum DSM 32105, Lactobacillus fermentum DSM 32110, Lactobacillus gasseri DSM 32103 , Lactobacillus mucosae DSM 32099 , Lactobacillus paracasei DSM 32106, Lactobacillus paracasei DSM 32097, Lactobacillus rhamnosus DSM 32114 or Lactobacillus rhamnosus DSM 32115.
3. The method of claim 2 , wherein the method further comprises administering to the subject Lactobacillus acidophilus NCFM, Bifidobacterium lactis BL-04 , Lactobacillus paracasei LPC37 , Bifidobacterium lactis HN019 or Bifidobacterium lactis Bi-07.
4. The method of claim 3 , wherein the method comprises administering to the subject Lactobacillus fermentum DSM 32109, Lactobacillus acidophilus NCFM, Bifidobacterium lactis BL-04 , Lactobacillus paracasei LPC37 , Bifidobacterium lactis HN019 and Bifidobacterium lactis Bi-07.
5. The method of claim 1 , wherein the gastrointestinal disorder comprises inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, constipation or diarrhea.
6. The method of claim 2 , wherein the method comprises administering to the subject a pharmaceutically effective amount of DSM 32109.
7. The method of claim 2 , wherein the gastrointestinal disorder comprises inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, constipation or diarrhea.
8. The method of claim 3 , wherein the gastrointestinal disorder comprises inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, constipation or diarrhea.
9. The method of claim 4 , wherein the gastrointestinal disorder comprises inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, constipation or diarrhea.
10. The method of claim 6 , wherein the gastrointestinal disorder comprises inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, constipation or diarrhea.